New Diabetes Drug Approved

On July 31, the U.S. Food and Drug Administration (FDA) approved the oral diabetes medicine[1] saxagliptin (brand name Onglyza), a joint development of Bristol-Myers Squibb and AstraZeneca. Onglyza will join Januvia[2] as a member of the class of drugs known as DPP-4 inhibitors[3].

DPP-4 inhibitors work to lower blood glucose by blocking the action of an enzyme known as dipeptidyl peptidase 4, or DPP-4. DPP-4 breaks down hormones called incretins, which stimulate the release of insulin[4], slow stomach emptying, inhibit the release of glucagon[5] (a hormone that signals the liver to release glucose), and enhance the survival and growth of the insulin-producing beta cells[6]. With DPP-4 inhibited, the incretins have longer to carry out these actions.

Onglyza will be offered in 2.5-milligram and 5-milligram doses to be taken once daily, with or without food. It is approved for use alone or in combination with metformin[7] (Glucophage and others), sulfonylureas[8] (DiaBeta, Glynase, Micronase, Glucotrol, Glucotrol XL, Amaryl), or thiazolidinediones[9] (Actos, Avandia) in adults with Type 2 diabetes[10]. Onglyza has not been studied in combination with insulin.

This medicine should not be used to treat Type 1 diabetes or diabetic ketoacidosis[11] (a potentially life-threatening condition marked by a chemical imbalance in the body). The most common side effects seen with the use of Onglyza are upper respiratory tract infection, headache, inflammation of the nasal passages, and urinary tract infection.

For more information about Onglyza, see the press release[12] on the Bristol-Myers Squibb Web site.

Endnotes:
  1. oral diabetes medicine: https://dsm.diabetesselfmanagement.com/articles/Oral-Medicines/
  2. Januvia: https://dsm.diabetesselfmanagement.com/Blog/Tara-Dairman/new_diabetes_drug_januvia_approved_by_fda/
  3. DPP-4 inhibitors: https://dsm.diabetesselfmanagement.com/Articles/Oral-Medicines/dpp-4-inhibitors/
  4. insulin: https://dsm.diabetesselfmanagement.com/Articles/Diabetes-Definitions/insulin/
  5. glucagon: https://dsm.diabetesselfmanagement.com/Articles/Diabetes-Definitions/glucagon/
  6. beta cells: https://dsm.diabetesselfmanagement.com/Articles/Diabetes-Definitions/beta_cells/
  7. metformin: https://dsm.diabetesselfmanagement.com/Articles/Diabetes-Definitions/metformin/
  8. sulfonylureas: https://dsm.diabetesselfmanagement.com/Articles/Diabetes-Definitions/sulfonylureas/
  9. thiazolidinediones: https://dsm.diabetesselfmanagement.com/Articles/Diabetes-Definitions/thiazolidinediones/
  10. diabetes: https://dsm.diabetesselfmanagement.com/Articles/Diabetes-Definitions/diabetes/
  11. diabetic ketoacidosis: https://dsm.diabetesselfmanagement.com/Articles/High-Blood-Glucose/hyperglycemic_crises/
  12. press release: http://www.bms.com/news/press_releases/pages/default.aspx?RSSLink=http://www.businesswire.com/news/bms/20090803006030/en&t=633858416419927284

Source URL: https://dsm.diabetesselfmanagement.com/blog/new-diabetes-drug-approved/


Diane Fennell: Diane Fennell has been an editor at Diabetes Self-Management magazine since 2003. She is currently the Editorial Director. (Diane Fennell is not a medical professional.)

Disclaimer of Medical Advice: Statements and opinions expressed on this Web site are those of the authors and not necessarily those of the publishers or advertisers. The information, which comes from qualified medical writers, does not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs.